Podcasts - 24 Nov `25Topical Rapamycin — Vitiligo’s Next Big Hope? (Ep. 54)

Podcast

Topical Rapamycin — Vitiligo’s Next Big Hope? (Ep. 54)

From Easter Island soil to modern skin science — meet rapamycin, the molecule that might just change vitiligo care.

Once known mainly as an anti-rejection drug for organ transplants, rapamycin is now being tested as a topical treatment that could both calm the immune attack and help pigment return. Early studies look promising: minimal side effects, slow but steady repigmentation, and surprisingly good tolerance.

In this episode, we explore:

  • How rapamycin rewires the skin’s immune balance
  • Why it’s called both a suppressor and a rejuvenator
  • What Phase II trials are revealing so far
  • And whether this “longevity drug” might also restore color to the skin

It’s too early to call it a breakthrough — but this little molecule from a far-off island might just be the next quiet revolution in vitiligo therapy.

Prefer reading? Topical Rapamycin: Could This Be Vitiligo’s Next Big Breakthrough?

🎙️ Listen to Deep Dive in Vitiligo

You can listen to Deep Dive in Vitiligo on your favorite podcast platform:

🍎 Apple Podcasts
🟢 Spotify
📦 Amazon Music
❤️ iHeart Radio
🎧 Player FM
🎙️ Podchaser
🎤 Podbean

Pick your platform, hit subscribe, and we'll meet you there.



No cover image

FAQOther Questions

  • What's the status with official recognition of World Vitiligo Day?

    In 2016, the United Nations marked World Vitiligo Day in its International Calendar of Disability Events. However, it was removed in 2019 when the calendar was streamlined to 'M...

  • Is there a special diet for vitiligo?

    Recent research highlights the potential of diet and nutrition in managing vitiligo, offering an alternative where traditional therapies may be lacking. However, the relationshi...

  • What is vitiligo?

     Vitiligo (pronounced vit-ill-EYE-go) is a generally unpredictable skin disease that causes a gradual loss of skin color and overlying hair on different parts of the body. Cont...